Cargando…
The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058693/ https://www.ncbi.nlm.nih.gov/pubmed/24935155 http://dx.doi.org/10.1186/1756-6606-7-45 |
_version_ | 1782321159649361920 |
---|---|
author | Yoshida, Tetsu Ozawa, Yoko Suzuki, Keiichiro Yuki, Kenya Ohyama, Manabu Akamatsu, Wado Matsuzaki, Yumi Shimmura, Shigeto Mitani, Kohnosuke Tsubota, Kazuo Okano, Hideyuki |
author_facet | Yoshida, Tetsu Ozawa, Yoko Suzuki, Keiichiro Yuki, Kenya Ohyama, Manabu Akamatsu, Wado Matsuzaki, Yumi Shimmura, Shigeto Mitani, Kohnosuke Tsubota, Kazuo Okano, Hideyuki |
author_sort | Yoshida, Tetsu |
collection | PubMed |
description | BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available clinical data are not always sufficient to elucidate the roles of these mutations in disease pathogenesis, a situation that is partially due to differences in genetic backgrounds. RESULTS: We generated induced pluripotent stem cells (iPSCs) from an RP patient carrying a rhodopsin mutation (E181K). Using helper-dependent adenoviral vector (HDAdV) gene transfer, the mutation was corrected in the patient’s iPSCs and also introduced into control iPSCs. The cells were then subjected to retinal differentiation; the resulting rod photoreceptor cells were labeled with an Nrl promoter-driven enhanced green fluorescent protein (EGFP)-carrying adenovirus and purified using flow cytometry after 5 weeks of culture. Using this approach, we found a reduced survival rate in the photoreceptor cells with the E181K mutation, which was correlated with the increased expression of endoplasmic reticulum (ER) stress and apoptotic markers. The screening of therapeutic reagents showed that rapamycin, PP242, AICAR, NQDI-1, and salubrinal promoted the survival of the patient’s iPSC-derived photoreceptor cells, with a concomitant reduction in markers of ER stress and apoptosis. Additionally, autophagy markers were found to be correlated with ER stress, suggesting that autophagy was reduced by suppressing ER stress-induced apoptotic changes. CONCLUSION: The use of RP patient-derived iPSCs combined with genome editing provided a versatile cellular system with which to define the roles of genetic mutations in isogenic iPSCs with or without mutation and also provided a system that can be used to explore candidate therapeutic approaches. |
format | Online Article Text |
id | pubmed-4058693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40586932014-06-17 The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa Yoshida, Tetsu Ozawa, Yoko Suzuki, Keiichiro Yuki, Kenya Ohyama, Manabu Akamatsu, Wado Matsuzaki, Yumi Shimmura, Shigeto Mitani, Kohnosuke Tsubota, Kazuo Okano, Hideyuki Mol Brain Research BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available clinical data are not always sufficient to elucidate the roles of these mutations in disease pathogenesis, a situation that is partially due to differences in genetic backgrounds. RESULTS: We generated induced pluripotent stem cells (iPSCs) from an RP patient carrying a rhodopsin mutation (E181K). Using helper-dependent adenoviral vector (HDAdV) gene transfer, the mutation was corrected in the patient’s iPSCs and also introduced into control iPSCs. The cells were then subjected to retinal differentiation; the resulting rod photoreceptor cells were labeled with an Nrl promoter-driven enhanced green fluorescent protein (EGFP)-carrying adenovirus and purified using flow cytometry after 5 weeks of culture. Using this approach, we found a reduced survival rate in the photoreceptor cells with the E181K mutation, which was correlated with the increased expression of endoplasmic reticulum (ER) stress and apoptotic markers. The screening of therapeutic reagents showed that rapamycin, PP242, AICAR, NQDI-1, and salubrinal promoted the survival of the patient’s iPSC-derived photoreceptor cells, with a concomitant reduction in markers of ER stress and apoptosis. Additionally, autophagy markers were found to be correlated with ER stress, suggesting that autophagy was reduced by suppressing ER stress-induced apoptotic changes. CONCLUSION: The use of RP patient-derived iPSCs combined with genome editing provided a versatile cellular system with which to define the roles of genetic mutations in isogenic iPSCs with or without mutation and also provided a system that can be used to explore candidate therapeutic approaches. BioMed Central 2014-06-16 /pmc/articles/PMC4058693/ /pubmed/24935155 http://dx.doi.org/10.1186/1756-6606-7-45 Text en Copyright © 2014 Yoshida et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yoshida, Tetsu Ozawa, Yoko Suzuki, Keiichiro Yuki, Kenya Ohyama, Manabu Akamatsu, Wado Matsuzaki, Yumi Shimmura, Shigeto Mitani, Kohnosuke Tsubota, Kazuo Okano, Hideyuki The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title | The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title_full | The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title_fullStr | The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title_full_unstemmed | The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title_short | The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
title_sort | use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058693/ https://www.ncbi.nlm.nih.gov/pubmed/24935155 http://dx.doi.org/10.1186/1756-6606-7-45 |
work_keys_str_mv | AT yoshidatetsu theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT ozawayoko theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT suzukikeiichiro theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT yukikenya theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT ohyamamanabu theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT akamatsuwado theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT matsuzakiyumi theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT shimmurashigeto theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT mitanikohnosuke theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT tsubotakazuo theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT okanohideyuki theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT yoshidatetsu useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT ozawayoko useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT suzukikeiichiro useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT yukikenya useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT ohyamamanabu useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT akamatsuwado useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT matsuzakiyumi useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT shimmurashigeto useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT mitanikohnosuke useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT tsubotakazuo useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa AT okanohideyuki useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa |